BioGend Therapeutics Co., Ltd. (TPEX:6733)

Market Cap	4.22B
Revenue (ttm)	156.64M
Net Income (ttm)	-109.93M
Shares Out	124.26M
EPS (ttm)	-0.89
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	84,000
Average Volume	71,442
Open	34.50
Previous Close	33.95
Day's Range	33.60 - 34.50
52-Week Range	31.40 - 42.30
Beta	0.63
RSI	56.04
Earnings Date	Mar 3, 2025

About BioGend Therapeutics

BioGend Therapeutics Co., Ltd. researches, develops, and sells orthopedic medical equipment and related products. It is developing BiG-001 and BiG-006, an osteoinductive bone graft substitute; and BiG-009, an autologous cartilage repair system. The company was incorporated in 2016 and is based in Taipei, Taiwan.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2016
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6733

Financial Performance

In 2023, BioGend Therapeutics's revenue was 109.91 million, an increase of 249.51% compared to the previous year's 31.45 million. Losses were -156.33 million, -15.25% less than in 2022.